Newsroom

韓国・インチョン--(BUSINESS WIRE)--（ビジネスワイヤ） -- サムスンバイオエピスは、エンタイビオ1（ベドリズマブ）を先行医薬品とするバイオシミラー候補品 SB36 を含む、同社が開発中の最大 5 品目のバイオシミラー候補品に関し、サンドとグローバルライセンス、開発および商品化契約（DCA）を締結したことを発表しました。契約のその他の条件については非開示となっています。 本契約の条件に基づき、サムスンバイオエピスがバイオシミラーの開発、主要市場における規制上の登録、製造を担当し、サンドが、中国、香港、台湾、マカオ、大韓民国を除く世界市場における商品化を担当します。 「サンドと成功したパートナーシップを拡大し、開発初期段階にある複数のバイオシミラー資産に関する商品化契約を締結できたことを大変喜ばしく思います。本契約は、人生を変えるような医薬品へのアクセスが限られている、衰弱性の疾患を患う患者のために、バイオ医薬品へのアクセス向上における重要な進展となります。」と、サムスンバイオエピスの社長兼最高経営責任者（CEO）のキム・キョンアは述べています。「サムスンバイオエピス...

CINCINNATI--(BUSINESS WIRE)--CBTS, a leading provider of managed IT and networking solutions, has been awarded HPE Triple Platinum Plus status, the highest within the HPE Partner Ready Vantage Program. This designation recognizes CBTS for outstanding commercial performance and strategic commitment across the full HPE portfolio. It is reserved only for strategic partners that meet rigorous sales thresholds at the country level and commit to sustained investments in technical certifications, comp...

LEWISVILLE, Texas--(BUSINESS WIRE)--Wan Bridge, a real estate and technology company shaping the future of residential living, today officially launched Frontera Shores, a vibrant new rental home community thoughtfully designed to meet the evolving lifestyle needs of modern families and fuel the continued growth of Lewisville. With a focus on innovation and resident experience, Frontera Shores marks a significant milestone in Wan Bridge’s commitment to delivering high-quality, professionally ma...

CHICAGO--(BUSINESS WIRE)--The FECK Awards, a powerful new national recognition program celebrating individuals who embody the transformative values of Forgiveness, Empathy, Compassion, and Kindness, today revealed the winners of its inaugural awards. Created by Chaz Ebert, CEO of Ebert Digital LLC and a longtime champion of empathy in storytelling and leadership, the FECK Awards were inspired by the principles outlined in her book It’s Time to Give a FECK: Elevating Humanity Through Forgiveness...

ATLANTA--(BUSINESS WIRE)--Wally Mlynarski has been named CEO of Elavon, a wholly owned subsidiary of U.S. Bank, delivering secure, scalable payments solutions and dedicated support to businesses across the United States, Europe and Canada. Mlynarski most recently led merchant services and receivables at Bank of America. He previously spent seven years with U.S. Bank supporting Elavon, where he held leadership roles including chief product officer. In his new role, Mlynarski will report to Mark...

SEATTLE--(BUSINESS WIRE)--Dropzone AI launches AI Threat Hunting, enhancing its Agentic SOC platform to help security teams proactively and continuously detect threats....

DALLAS--(BUSINESS WIRE)--LTK, the company that turned influence into a global economy, today introduced Quick Collabs, a new feature within the LTK Brand Platform designed to make it easier and faster for brands and creators to work together. Designed to remove the friction that slows creator marketing down, Quick Collabs is the fastest, lowest-commitment way to activate creators on LTK. Quick Collabs are flat-fee campaigns that brands can launch in minutes, enabling creators to opt in and get...

INCHEON, Corée--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. a annoncé aujourd’hui la conclusion d’un accord mondial de licence, de développement et de commercialisation (DCA) avec Sandoz, portant sur un maximum de cinq candidats biosimilaires actuellement en développement au sein de Samsung Bioepis, dont SB36, un candidat biosimilaire ayant pour produit de référence Entyvio1 (vedolizumab). Les autres modalités de l’accord demeurent confidentielles. Aux termes de l’accord, Samsung Bioepis sera re...

INCHEON, Korea--(BUSINESS WIRE)--Vandaag maakte Samsung Bioepis Co., Ltd. bekend dat het bedrijf een wereldwijde DCA-licentie (Development & Commercialization Agreement) heeft gesloten met Sandoz voor in totaal vijf biosimilaire kandidaatgeneesmiddelen die momenteel door Samsung Bioepis worden ontwikkeld, waaronder SB36, een biosimilair kandidaatgeneesmiddel gelijkwaardig aan Entyvio1 (vedolizumab). Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts al...

INCHEON, Corea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. oggi ha annunciato la sigla con Sandoz di un accordo di licenza, sviluppo e commercializzazione (DCA) globale che riguarderà fino a cinque candidati biosimilari in corso di sviluppo da parte di Samsung Bioepis, tra cui SB36, un candidato biosimilare di Entyvio1 (vedolizumab). Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità...